Skip to main content
NCBI home page
Biochemical Journal logoLink to Biochemical Journal
. 1998 Mar 1;330(Pt 2):833–838. doi: 10.1042/bj3300833

Amino acid substitutions in the N-terminal segment of cystatin C create selective protein inhibitors of lysosomal cysteine proteinases.

R W Mason 1, K Sol-Church 1, M Abrahamson 1
PMCID: PMC1219213  PMID: 9480898

Abstract

We used site-directed mutagenesis to alter the specificity of human cystatin C, an inhibitor with a broad reactivity against cysteine proteinases. Nine cystatin C variants containing amino acid substitutions in the N-terminal (L9W, V10W, V10F and V10R) and/or the C-terminal (W106G) enzyme-binding regions were designed and produced in Escherichia coli. It was discovered that the inhibition profile of the cystatin could be altered by changing residues 9 and 10, which are proposed to bind in the S3 and S2 substrate-binding pockets respectively of the enzymes. All of the variants with substitutions in the N-terminal segment displayed decreased binding to cathepsins B and H, indicating that the S3 and S2 pockets of these enzymes cannot easily accommodate large aromatic residues. The introduction of a charged residue into S2 (variant V10R) created a more specific inhibitor to distinguish cathepsin B from cathepsin H. Cathepsin L showed a preference for larger aromatic residues in S2. In contrast, cathepsin S preferred phenylalanine to valine in S2, but bound less tightly to the V10W cystatin variant. The latter variant proved to be valuable for discriminating between cathepsin L and cathepsin S (Ki 2.4 and 190 pM respectively). The equilibrium dissociation constant of the complex between cathepsin L and variant L9W/W106G showed little difference in affinity from that of the cathepsin L complex with the singly substituted W106G variant. In contrast, the L9W/W106G variant displayed increased specificity for cathepsin S with a Ki of 10 pM. Our results clearly indicate differences in the specificity of interaction between the N-terminal region of cystatin C and cathepsins B, H, L and S, and that, although cystatin C has evolved to be a good inhibitor of all of the mammalian cysteine proteinases, more specific inhibitors of the individual enzymes can be engineered.

Full Text

The Full Text of this article is available as a PDF (297.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abrahamson M., Dalbøge H., Olafsson I., Carlsen S., Grubb A. Efficient production of native, biologically active human cystatin C by Escherichia coli. FEBS Lett. 1988 Aug 15;236(1):14–18. doi: 10.1016/0014-5793(88)80276-x. [DOI] [PubMed] [Google Scholar]
  2. Abrahamson M., Ritonja A., Brown M. A., Grubb A., Machleidt W., Barrett A. J. Identification of the probable inhibitory reactive sites of the cysteine proteinase inhibitors human cystatin C and chicken cystatin. J Biol Chem. 1987 Jul 15;262(20):9688–9694. [PubMed] [Google Scholar]
  3. Barrett A. J., Kembhavi A. A., Brown M. A., Kirschke H., Knight C. G., Tamai M., Hanada K. L-trans-Epoxysuccinyl-leucylamido(4-guanidino)butane (E-64) and its analogues as inhibitors of cysteine proteinases including cathepsins B, H and L. Biochem J. 1982 Jan 1;201(1):189–198. doi: 10.1042/bj2010189. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Barrett A. J., Kirschke H. Cathepsin B, Cathepsin H, and cathepsin L. Methods Enzymol. 1981;80(Pt 100):535–561. doi: 10.1016/s0076-6879(81)80043-2. [DOI] [PubMed] [Google Scholar]
  5. Björk I., Pol E., Raub-Segall E., Abrahamson M., Rowan A. D., Mort J. S. Differential changes in the association and dissociation rate constants for binding of cystatins to target proteinases occurring on N-terminal truncation of the inhibitors indicate that the interaction mechanism varies with different enzymes. Biochem J. 1994 Apr 1;299(Pt 1):219–225. doi: 10.1042/bj2990219. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bode W., Engh R., Musil D., Thiele U., Huber R., Karshikov A., Brzin J., Kos J., Turk V. The 2.0 A X-ray crystal structure of chicken egg white cystatin and its possible mode of interaction with cysteine proteinases. EMBO J. 1988 Aug;7(8):2593–2599. doi: 10.1002/j.1460-2075.1988.tb03109.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Brömme D., Klaus J. L., Okamoto K., Rasnick D., Palmer J. T. Peptidyl vinyl sulphones: a new class of potent and selective cysteine protease inhibitors: S2P2 specificity of human cathepsin O2 in comparison with cathepsins S and L. Biochem J. 1996 Apr 1;315(Pt 1):85–89. doi: 10.1042/bj3150085. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Brömme D., Steinert A., Friebe S., Fittkau S., Wiederanders B., Kirschke H. The specificity of bovine spleen cathepsin S. A comparison with rat liver cathepsins L and B. Biochem J. 1989 Dec 1;264(2):475–481. doi: 10.1042/bj2640475. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Casadaban M. J., Cohen S. N. Analysis of gene control signals by DNA fusion and cloning in Escherichia coli. J Mol Biol. 1980 Apr;138(2):179–207. doi: 10.1016/0022-2836(80)90283-1. [DOI] [PubMed] [Google Scholar]
  10. Crawford C., Mason R. W., Wikstrom P., Shaw E. The design of peptidyldiazomethane inhibitors to distinguish between the cysteine proteinases calpain II, cathepsin L and cathepsin B. Biochem J. 1988 Aug 1;253(3):751–758. doi: 10.1042/bj2530751. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. DIXON M. The determination of enzyme inhibitor constants. Biochem J. 1953 Aug;55(1):170–171. doi: 10.1042/bj0550170. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hall A., Dalbøge H., Grubb A., Abrahamson M. Importance of the evolutionarily conserved glycine residue in the N-terminal region of human cystatin C (Gly-11) for cysteine endopeptidase inhibition. Biochem J. 1993 Apr 1;291(Pt 1):123–129. doi: 10.1042/bj2910123. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hall A., Håkansson K., Mason R. W., Grubb A., Abrahamson M. Structural basis for the biological specificity of cystatin C. Identification of leucine 9 in the N-terminal binding region as a selectivity-conferring residue in the inhibition of mammalian cysteine peptidases. J Biol Chem. 1995 Mar 10;270(10):5115–5121. doi: 10.1074/jbc.270.10.5115. [DOI] [PubMed] [Google Scholar]
  14. Henderson P. J. A linear equation that describes the steady-state kinetics of enzymes and subcellular particles interacting with tightly bound inhibitors. Biochem J. 1972 Apr;127(2):321–333. doi: 10.1042/bj1270321. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Mason R. W., Green G. D., Barrett A. J. Human liver cathepsin L. Biochem J. 1985 Feb 15;226(1):233–241. doi: 10.1042/bj2260233. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Mason R. W. Species variants of cathepsin L and their immunological identification. Biochem J. 1986 Nov 15;240(1):285–288. doi: 10.1042/bj2400285. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Ménard R., Carmona E., Plouffe C., Brömme D., Konishi Y., Lefebvre J., Storer A. C. The specificity of the S1' subsite of cysteine proteases. FEBS Lett. 1993 Aug 9;328(1-2):107–110. doi: 10.1016/0014-5793(93)80975-z. [DOI] [PubMed] [Google Scholar]
  18. Xin X. Q., Gunesekera B., Mason R. W. The specificity and elastinolytic activities of bovine cathepsins S and H. Arch Biochem Biophys. 1992 Dec;299(2):334–339. doi: 10.1016/0003-9861(92)90283-3. [DOI] [PubMed] [Google Scholar]
  19. Zumbrunn A., Stone S., Shaw E. Synthesis and properties of Cbz-Phe-Arg-CHN2 (benzyloxycarbonylphenylalanylarginyldiazomethane) as a proteinase inhibitor. Biochem J. 1988 Mar 1;250(2):621–623. doi: 10.1042/bj2500621. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Biochemical Journal are provided here courtesy of The Biochemical Society

RESOURCES